Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis
Open Access
- 26 May 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 18 (2) , 195-200
Abstract
Acute intermittent porphyria (AIP) is an autosomal-dominant condition resulting from a partial deficiency of the ubiquitously expressed enzyme porphobilinogen deaminase. Although its clinical expression is highly variable, a minority of patients suffer recurrent life-threatening neurovisceral attacks despite optimal medical therapy. Because the liver is the major source of excess precursor production, liver transplantation (LT) represents a potentially effective treatment for severely affected patients. Using data from the UK Transplant Registry, we analyzed all transplants performed for AIP in the United Kingdom and Ireland. Between 2002 and 2010, 10 patients underwent LT for AIP. In all cases, the indication for transplantation was recurrent, biochemically proven, medically nonresponsive acute attacks of porphyria resulting in significantly impaired quality of life. Five patients had developed significant neurological morbidities such as paraplegia before transplantation. The median follow-up time was 23.4 months, and there were 2 deaths from multiorgan failure at 98 days and 26 months. Eight recipients were alive for 3.2 to 109 months after transplantation. Complete biochemical and symptomatic resolution was observed in all patients after transplantation. However, there was a high rate of hepatic artery thrombosis (HAT; 4/10), with 1 patient requiring regrafting. The effects of previous neuronal damage such as joint contractures were not improved by transplantation. Thus, impaired quality of life in the surviving patients was usually a result of preoperative complications. Refractory AIP is an excellent indication for LT, and long-term outcomes for carefully selected patients are good. There is, however, an increased incidence of HAT in these patients, and we recommend routine antiplatelet therapy after transplantation. Liver Transpl 18:195–200, 2012. © 2011 AASLD.Keywords
Funding Information
- Cardiff University
- James University Hospital (Leeds, United Kingdom)
- University Hospital (Dublin, Ireland)
This publication has 19 references indexed in Scilit:
- PorphyriasThe Lancet, 2010
- Liver transplantation for acute intermittent porphyria: a viable treatment?2010
- Diagnostic Strategies for Autosomal Dominant Acute Porphyrias: Retrospective Analysis of 467 Unrelated Patients Referred for Mutational Analysis of the HMBS, CPOX, or PPOX GeneClinical Chemistry, 2009
- Acute intermittent porphyria and chronic renal failureClinical Nephrology, 2008
- Adult Orthotopic Liver Transplantation in the United Kingdom and Ireland Between 1994 and 2005Transplantation, 2007
- Liver transplantation for porphyria: Who, when, and how?Liver Transplantation, 2007
- Recommendations for the Diagnosis and Treatment of the Acute PorphyriasAnnals of Internal Medicine, 2005
- Liver transplantation as a cure for acute intermittent porphyriaThe Lancet, 2004
- Renal symptomatology in patients with acute intermittent porphyria. A population‐based studyJournal of Internal Medicine, 2000
- Acute Porphyrias: Pathogenesis of Neurological ManifestationsSeminars in Liver Disease, 1998